|
Editorial
Biomarkers and Personalized Sorafenib Therapy
Kudo, M.
Liver Cancer 2014;3:399–404
Reviews
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Choi, C.; Choi, G.H.; Kim, T.H.; Tanaka, M.; Meng, M.-B.; Seong, J.
Liver Cancer 2014;3:405–416
Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications
Nishida, N.; Kudo, M.
Liver Cancer 2014;3:417–427
Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law
Lake-Bakaar, G.; Ahmed, M.; Evenson, A.; Bonder, A.; Faintuch, S.; Sundaram, V.
Liver Cancer 2014;3:428–438
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
Raoul, J.-L.; Park, J.-W.; Kang, Y,-K.; Finn, R.S.; Kim, J.S.; Yeo, W.; Polite, B.N.; Chao, Y.; Walters, I.; Baudelet, C.; Lencioni, R.
Liver Cancer 2014;3:439–450
Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5) Represents a Typical Wnt/ß-Catenin Pathway-Activated Hepatocellular Carcinoma
Effendi, K.; Yamazaki, K.; Fukuma, M.; Sakamoto, M.
Liver Cancer 2014;3:451–457
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Kudo, M.; Matsui, O.; Izumi, N.; Iijima, H.; Kadoya, M.; Imai, Y.; Okusaka, T.; Miyayama, S.; Tsuchiya, K.; Ueshima, K.; Hiraoka, A.; Ikeda, M.; Ogasawara, S.; Yamashita, T.; Minami, T.; Yamakado, K.; on behalf of the Liver Cancer Study Group of Japan
Liver Cancer 2014;3:458–468
Abstracts
The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014), A Bridge to a Consensus on HCC Management, Taipei, Taiwan, July 11-13, 2014: Abstracts
Liver Cancer 2014;3:285-397
|
